Calix Ltd (ASX: CXL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Calix Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$146.67 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
182.20 million
Earnings per share
-0.144
Dividend per share
N/A
Year To Date Return
-76.53%
Earnings Yield
N/A
Franking
100%
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Calix Ltd (ASX: CXL)
Latest News
Technology Shares
Guess which ASX 300 stock is rocketing 15% today
Share Market News
Why Calix, Collins Foods, Myer, and Patriot Battery Metals shares are charging higher
Technology Shares
Guess which ASX tech stock could double in value
Share Market News
Insiders are buying Mesoblast and these ASX shares
Share Gainers
Why Calix, Genex, Life360, and Spartan Resources shares are rising
Technology Shares
Guess which ASX tech stock is jumping 15% today
Share Fallers
Why Ampol, Calix, Collins Foods, and Propel shares are tumbling today
Share Gainers
Why Audinate, Beach Energy, Calix, and JB Hi-Fi shares are charging higher
Share Fallers
Why Boss Energy, Calix, Frontier Digital, and Gold Road shares are falling today
Materials Shares
Why is this ASX All Ords share plunging 30% on Monday?
Broker Notes
Top brokers name 3 ASX shares to buy today
Share Gainers
Why Calix, Chrysos, Inghams, and Life360 shares are pushing higher today
Frequently Asked Questions
-
Calix Ltd does not pay shareholder dividends at this time.
-
Calix listed on the ASX on 20 July 2018.
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 26 Sep 2005 | $0.0150 | 100.00% | Final | 07 Oct 2005 |
CXL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Calix Ltd
Calix Ltd (ASX: CXL) is an Australian technology company. It has developed a patented, platform technology that essentially involves grinding minerals to between one-hundredth and one-thousandth of a millimetre in size, and then "flash" heating them in a reactor. As trapped gases in the minerals are released, they create highly porous honeycomb-like structures with similar properties to nanomaterials, but without the associated safety issues and costs. Calix's technology also allows for the separation of carbon dioxide, making it attractive to industries and companies looking to reduce carbon emissions.
Calix's technology is being used globally across many industries and sectors. These include advanced battery development, water and wastewater treatment, sustainable food, and biotechnology. The company has operations in Australia, New Zealand, Asia, Europe, and the United States.
CXL Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 22 Nov 2024 | $0.81 | $0.01 | 1.25% | 241,270 | $0.81 | $0.83 | $0.80 |
| 21 Nov 2024 | $0.80 | $-0.01 | -1.24% | 175,788 | $0.81 | $0.83 | $0.80 |
| 20 Nov 2024 | $0.81 | $-0.04 | -4.71% | 242,974 | $0.84 | $0.88 | $0.81 |
| 19 Nov 2024 | $0.85 | $0.01 | 1.19% | 76,881 | $0.84 | $0.86 | $0.83 |
| 18 Nov 2024 | $0.84 | $0.00 | 0.00% | 130,830 | $0.84 | $0.87 | $0.83 |
| 15 Nov 2024 | $0.84 | $-0.04 | -4.57% | 423,122 | $0.86 | $0.89 | $0.84 |
| 14 Nov 2024 | $0.88 | $0.03 | 3.53% | 153,720 | $0.87 | $0.92 | $0.86 |
| 13 Nov 2024 | $0.85 | $0.02 | 2.41% | 203,122 | $0.84 | $0.91 | $0.84 |
| 12 Nov 2024 | $0.83 | $-0.01 | -1.20% | 74,476 | $0.83 | $0.86 | $0.83 |
| 11 Nov 2024 | $0.84 | $-0.02 | -2.35% | 248,034 | $0.84 | $0.88 | $0.83 |
| 08 Nov 2024 | $0.85 | $0.04 | 4.97% | 72,443 | $0.82 | $0.85 | $0.82 |
| 07 Nov 2024 | $0.81 | $-0.01 | -1.23% | 408,753 | $0.82 | $0.85 | $0.78 |
| 06 Nov 2024 | $0.82 | $0.00 | 0.00% | 94,890 | $0.82 | $0.85 | $0.81 |
| 05 Nov 2024 | $0.82 | $-0.03 | -3.55% | 134,780 | $0.86 | $0.86 | $0.82 |
| 04 Nov 2024 | $0.85 | $-0.05 | -5.62% | 298,909 | $0.90 | $0.90 | $0.83 |
| 01 Nov 2024 | $0.89 | $0.01 | 1.13% | 115,098 | $0.90 | $0.91 | $0.86 |
| 31 Oct 2024 | $0.89 | $0.04 | 4.71% | 478,280 | $0.85 | $0.90 | $0.85 |
| 30 Oct 2024 | $0.85 | $-0.15 | -15.08% | 1,728,918 | $0.78 | $0.87 | $0.73 |
| 29 Oct 2024 | $1.00 | $-0.05 | -4.81% | 277,622 | $1.02 | $1.04 | $0.99 |
| 28 Oct 2024 | $1.04 | $0.05 | 5.05% | 164,826 | $0.99 | $1.05 | $0.98 |
| 25 Oct 2024 | $0.99 | $-0.01 | -1.01% | 163,744 | $0.98 | $1.02 | $0.98 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 03 May 2024 | Sarah Ryan | Buy | 10,000 | $13,500 |
On-market trade.
|
| 10 Apr 2024 | Sarah Ryan | Buy | 10,000 | $14,950 |
On-market trade.
|
| 12 Mar 2024 | Catriona Deans | Buy | 50,000 | $86,500 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Catriona Alison Deans | Non-Executive DirectorNon-Executive Chairman | Mar 2023 |
Ms Deans is also a member of the Investment Committee at Main Sequence Ventures (CSIRO's innovation fund) and a Member of the AICD Corporate Governance Committee. Alison's previous directorships include Westpac Banking Corporation, Insurance Australia Group Limited and Social Ventures Australia. In her executive career, Alison was previously the CEO of eBay Australia and New Zealand, CEO of eCorp Limited (a publicly listed portfolio of digital businesses), CEO of Hoyts Cinemas, CEO of netus Pty Ltd (a technology investment company acquired by Fairfax), and a consultant with McKinsey & Company. She is member of Risk Management Committee and the Sustainability Committee.
|
| Ms Helen E Fisher | Non-Executive Director | Sep 2020 |
Ms Fisher is Managing Director and CEO of Bio Capital Impact Fund (BCIF). Prior to establishing BCIF, Helen was a partner of Deloitte for over 10 years and led Deloitte's Life Sciences industry practice in Australia for five years, having had many years of experience in the Life Sciences and Health Care industry. She also specialized in Financial Services, servicing some of the Australian banks and funds and has been involved in setting up several international funds, as well as advised on several M&A deals. Helen provided strategic advice to publicly listed multinational companies and has experience with capital raisings, licensing deals, demergers, implementing offshore expansions. She is Chair of the Risk Management Committee and member of the Sustainability Committee.
|
| Mr Lance Adrian Wingate O'Neill | Non-Executive Director | Feb 2014 |
Lance O'Neill is a Director of DFB (Australia) Pty Ltd, a Sydney based investment advisory business, and has worked in institutional equity, fixed income sales/trading and corporate finance in international securities and investment markets for over thirty years predominantly in Australia, UK and USA. He is the chair of MediaZest Plc and EP&F Capital Plc and in addition is and has been a director of, and investor in, a number of private and public companies in Australia, UK, and the USA.
|
| Dr Mark Geoffrey Sceats | Chief ScientistExecutive Director | Feb 2014 |
Dr Sceats has previously worked at the James Franck Institute at the University of Chicago, and a Research Associate, and as an Assistant Professor of the University of Rochester NY, USA, where he was awarded the Alfred P Sloan Fellowship for his work. Later he was employed by the University of Sydney as a Reader in the School of Chemistry for his research work on chemical reaction kinetics and led the Australian Photonics CRC from 1991-2004. He is also member of the Technology Committee.
|
| Dr Philip (Phil) Hargraves Hodgson | Chief Executive OfficerManaging Director | Feb 2014 |
Dr Hodgson has a technical and commercial background from a career with Shell, where for over 14 years he developed depth of experience across all sectors of the downstream oil industry, including refining and supply, marketing and sales, pricing strategy, risk management, corporate strategy, and mergers and acquisitions. From 2007 to 2013, Phil ran his own consultancy, providing project development, commercial, M&A, and management expertise to several sectors, including LNG, biofuel, clean coal, geothermal energy, building products, logistics and fast-moving consumer goods. He is also member of Technology Committee.
|
| Dr Sarah Elizabeth Ryan | Non-Executive Director | Jan 2024 |
Dr Ryan brings global engineering and commercial experience, encompassing private equity, investment management, energy sector operations, marketing, research, and team management. With a particular emphasis on innovation and technology enabled solutions. Dr Ryan is also a Strategic Advisory Panel Member of the ARC Centre of Excellence for Green Electrochemical Transformation of Carbon Dioxide and Chair of the Energy Forum for the Australian Academy of Technological Sciences and Engineering.
|
| Mr Peter Matthew Francis Dixon | Non-Executive Director | Jan 2024 |
Mr Dixon has 25 years of experience across the legal, investment banking and funds management sectors, Mr Dixon brings expertise across corporate strategy, investment management, corporate advisory (including equity capital markets) and legal governance issues to the Calix board. Mr Dixon is currently Chief Strategy Officer for HPX. Mr Dixons investment banking and legal experience includes private legal practice experience at Mallesons Stephen Jacques in Sydney and Linklaters in London, as well as over nine years executive experience as an investment banker.
|
| Mr Darren Charles | Chief Financial OfficerCompany Secretary |
-
|
|
| Darren Charles | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| J P Morgan Nominees Australia Pty Limited | 37,306,915 | 20.49% |
| HSBC Custody Nominees (Australia) Limited | 16,902,940 | 9.29% |
| UBS Nominees Pty Ltd | 14,434,134 | 7.93% |
| Nicholas Merriman | 8,108,286 | 4.45% |
| Citicorp Nominees Pty Limited | 6,978,187 | 3.83% |
| Mr Paul Crowther | 5,389,438 | 2.96% |
| Mark Geoffrey Sceats <Sceats Superannuation Fund> | 2,847,344 | 1.56% |
| Dr Mark Geoffrey Sceats | 2,732,119 | 1.50% |
| Pigeons Super Pty Limited <The Hodgson Family S/F A/C> | 2,196,597 | 1.21% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 1,889,808 | 1.04% |
| UBS Nominees Pty Ltd i | 1,773,836 | 0.97% |
| Mr Jacob Shields Ulrich | 1,533,133 | 0.84% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 1,497,250 | 0.82% |
| Phil Hodgson | 1,311,148 | 0.72% |
| Jeneil Super Pty Ltd <Jeneil Super Fund A/C> | 1,266,387 | 0.70% |
| Mr John Andrew Hamilton | 1,223,639 | 0.67% |
| Turnbull Super Fund Pty Ltd <The Turnbull Super Fund A/C> | 1,133,789 | 0.62% |
| Mr Maxwell Oliver Crowther | 1,000,000 | 0.55% |
| Mr Oliver Marcus Crowther | 1,000,000 | 0.55% |
| Ms Megan Olivia Crowther | 1,000,000 | 0.55% |
